Status: Recruiting
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
Prospective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks
Participants needed: 124
Trial details
Phase: Phase 3Age: 2+Biological sex: AllType: InterventionalSponsor: OctapharmaUpdated: Jun 30, 2026Locations: 21
Eligibility criteria
Is at least 18 years of age (applicable for 1st study phase) or is at least 2 ye... [+14]
Has a history of clinically relevant antibody development against C1-INH [+22]